Li Juan, Ling Xuebing, Lai Mingyao, Hu Qingjun, Shan Changguo, Cai Linbo
Department of Oncology, Guangdong 999 Brain Hospital, Guangzhou 510510, China.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2018 Apr 28;43(4):398-402. doi: 10.11817/j.issn.1672-7347.2018.04.010.
To retrospectively summarize the clinicopathological features of epithelioid glioblastoma (Ep-GBM) and to explore new treatment for Ep-GBM. Methods: The clinical data of 13 patients with Ep-GBM, who were treated in our department from March 2016 to July 2017, were retrospectively analyzed. The clinicopathological features were summarized and the efficacy was evaluated. Results: The positive rate of BRAFV600E mutant and INI-1 was 76.9% (10/13) and 80% (8/10), respectively, while the median Ki-67 index was 30%. Meningeal metastases occurred in 9 cases (69.7%) during the course. The median follow-up time was 12 (6-25) months, and the median progression-free time was 8.6 (2.2-16.5) months. Three patients died and the 1-year overall survival rate was 54%. Conclusion: Ep-GBM has a high degree of malignancy and is prone to spread to leptomeninges. INI-1 expression and BRAFV600E mutation are common for Ep-GBM. BRAF inhibitor might be a potential therapeutic drug for it.
回顾性总结上皮样胶质母细胞瘤（Ep-GBM）的临床病理特征，并探索Ep-GBM的新治疗方法。方法：回顾性分析2016年3月至2017年7月在我科治疗的13例Ep-GBM患者的临床资料。总结临床病理特征并评估疗效。结果：BRAFV600E突变和INI-1的阳性率分别为76.9%（10/13）和80%（8/10），而Ki-67指数中位数为30%。病程中9例（69.7%）发生脑膜转移。中位随访时间为12（6-25）个月，中位无进展时间为8.6（2.2-16.5）个月。3例患者死亡，1年总生存率为54%。结论：Ep-GBM恶性程度高，易扩散至软脑膜。INI-1表达和BRAFV600E突变在Ep-GBM中常见。BRAF抑制剂可能是其潜在的治疗药物。
